LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Strona główna・Stock List・Prothena Corp PLC

Prothena Corp PLC

Closed

Sector Healthcare

20.36 -1.02

Buy Sell

Overview

Share price change

24h

Current

Min

20.26

Max

20.59

Key metrics
By Trading Economics
Income	-72M
Sales	-266K 50K
EPS	-1.34
Profit margin	-144,478
EBITDA	-81M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+235.1 upside

Dividends
By Dow Jones
Next Earnings	31 paź 2024

Market Stats
By TradingEconomics
Market Cap	38M 1.2B
Previous open	21.38
Previous close	20.36

News Sentiment

By Acuity

100%

340 / 365 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 21.2 Support & Resistance

Prothena Corp PLC Chart

Related News

28 maj 2024, 22:51 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

Peer Comparison

Price change

Prothena Corp PLC Forecast

Price Target

By TipRanks

235.1% upside

12 Months Forecast

Average 69.5 USD 235.1%

High 94 USD

Low 24 USD

Based on 6 Wall Street analysts offering 12 month price targets forProthena Corp PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Prothena Corp PLC - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 21.2Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

340 / 365 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

EBITDA

Operating profit

About Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.